
The research identifies that the inactivation of protein phosphatase 2A (PP2A) subunits, including PPP2R1A, enhances ATR inhibitor (ATRi) sensitivity in ARID1A mutant OCCC. Analysis of patient cohorts revealed that 52% of OCCC cases possess oncogenic PPP2R1A mutations. In vitro and in vivo models showed that PPP2R1A mutations lead to genomic instability and ATRi sensitivity, suggesting PPP2R1A mutations as a biomarker for ATRi therapy.
Like
Save
Share